Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa

BACKGROUND: Lamivudine (3TC) is a potent inhibitor of both Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) replication and is part of first-line highly active antiretroviral therapy (HAART) in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stewart, Balint, Jobarteh, Modou L, Sarge-Njie, Ramu, Alabi, Abraham, de Silva, Thushan, Peterson, Kevin, Peterson, Ingrid, Whittle, Hilton, Rowland-Jones, Sarah, Jaye, Assan, Cotten, Matthew, Mendy, Maimuna
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2011
Gaiak:
Short Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3292846/
https://ncbi.nlm.nih.gov/pubmed/22195774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-4-561
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak